文献速递类风湿关节炎脊柱关节炎其他结缔组织病

实体瘤患者接受免疫检查点抑制剂后既有风湿病复发的发生率:系统评价与荟萃分析

Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2026-01-31

该系统评价与荟萃分析纳入31项研究、超过700例患者,评估实体瘤患者接受免疫检查点抑制剂(ICI)后既有风湿病复发的发生率和严重程度。汇总的1-5级复发发生率为33.8%(95%CI 25.8-42.2%),中位起病时间38.5天;3-5级复发发生率为4.2%(95%CI 0.6-9.6%)。不同风湿病复发率存在差异,类风湿关节炎为40.9%,银屑病关节炎为46.4%,系统性硬化症为11.3%,系统性红斑狼疮为3.8%。

要点

  • ICI治疗后既有风湿病1-5级复发汇总发生率为33.8%,中位起病38.5天。
  • 3-5级严重复发发生率为4.2%,不同风湿病类型复发率差异明显。
  • 83%复发患者接受全身糖皮质激素治疗,81%临床改善,17%永久停用ICI。

核心结论

  • 实体瘤患者接受ICI后既有风湿病复发发生率因基础风湿病类型而异,需风湿科与肿瘤科密切协作评估风险并管理复发。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed和Embase至2024年5月,纳入31项报告ICI相关既有风湿病复发发生 rates 的研究,共超过700例患者,采用随机效应比例荟萃分析。

主要发现

  • 1-5级复发汇总发生率为33.8%(95%CI 25.8-42.2%),中位起病时间为ICI启动后38.5天(IQR 30.0-52.6)。
  • 3-5级复发汇总发生率为4.2%(95%CI 0.6-9.6)。
  • 类风湿关节炎复发率为40.9%,银屑病关节炎为46.4%,系统性硬化症为11.3%,系统性红斑狼疮为3.8%。
  • 复发 cases 中83%(n=134/161)接受全身糖皮质激素治疗,其中81%(n=30/37)临床改善;17%的复发 cases 永久停用ICI。

关键数值与推荐

  • 1-5级复发发生率33.8%(95%CI 25.8-42.2%),3-5级复发发生率4.2%(95%CI 0.6-9.6)。
  • 类风湿关节炎复发率40.9%,银屑病关节炎46.4%,系统性硬化症11.3%,系统性红斑狼疮3.8%。
  • 中位起病时间38.5天(IQR 30.0-52.6)。

临床怎么用

  • ICI启动前应由风湿科与肿瘤科共同评估既有风湿病复发风险,启动后密切监测,尤其关注起病中位时间38.5天内的复发迹象。
  • 复发后多数患者可通过全身糖皮质激素控制,但部分需永久停用ICI,需权衡肿瘤治疗获益与风湿病复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitors (ICIs) are increasingly used in oncology, but concerns persist regarding flare risks of pre-existing rheumatologic diseases in patients receiving ICIs. This meta-analysis study aims to evaluate the incidence and severity of rheumatologic disease flares in patients with solid tumors treated with ICIs. METHODS: We searched PubMed and Embase through May 2024 to identify studies reporting the incidences of pre-existing rheumatologic disease flare due to ICIs for their cancer. A random-effects proportional meta-analysis was conducted to pool the incidence of grade 1-5 and grade 3-5 flares, stratified by rheumatologic disease types and ICI subtypes. RESULTS: In total, 31 studies comprising more than 700 patients were identified for meta-analyses. The pooled incidence of grade 1-5 flare was 33.8% (95% confidence interval [CI]: 25.8-42.2%), with a median onset of 38.5 days (IQR: 30.0-52.6) after ICI initiation. Grade 3-5 flare incidence rate was 4.2% (95% CI: 0.6-9.6). Flare incidences varied among rheumatologic diseases: 40.9% in rheumatoid arthritis, 46.4% in psoriatic arthritis, 11.3% in systemic sclerosis, and 3.8% in systemic lupus erythematosus, respectively. For disease flares, 83% (n = 134/161) received systemic corticosteroids, and 81% (n = 30/37) of such cases had clinical improvement. ICIs were permanently discontinued in 17% of flare cases. CONCLUSIONS: Incidences of rheumatologic disease flare from ICIs vary depending on the underlying rheumatologic condition. This underscores the need for close communication between rheumatologists and oncologists to assess risk of flares prior to ICI initiation and manage both rheumatologic disease and cancer after the incidences of disease flares.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Yamada K, Matsui T, Takahashi T, et al. Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Semin Arthritis Rheum. 2026. PMID: 41643573. doi:10.1016/j.semarthrit.2026.152938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。